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ABSTRACT

The opioid crisis is a pervasive and social problem in the United States. Since 2001 several
hundred thousand people have died from the misuse of prescription and illicit opioids. On
average nearly 130 Americans perish every day due to opioid abuse while millions annually
struggle with morbidity derived from opioid abuse disorders. This crisis causes tremendous
physical and emotional suffering and death and is likely the most profound public health crisis
our nation has faced. In 2015 alone, 52,000 people died of drug overdoses, with over 30,000 of
those dying from opioid drugs. If left unchecked, the epidemic will continue to increase, and
more of the population will continue to be affected by the opioid abuse. Literature related to
opioid abuse is vast and expansive. However, the literature is lacking in the area of screening
during the initial assessment to indicate the abuse potential. Findings derived from the literature
show consistent support in the need for methodologies and interventions that prompt intervention
or assist providers in the assessment of patients requiring opioids for management of chronic
pain with the result to stalemate the opioid abuse in society. With this in mind, the purpose of
this project is to determine whether the use of an opioid screening tool at the time of initial
assessment of patients with chronic non-cancer pain will decrease the use of opioid use.
Keywords: Opioid, abuse, overdose prevention, screening tools, therapeutic opioid use, pain
management, chronic pain, and opioid crisis
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SECTION ONE: FORMULATING THE REVIEW QUESTION
Introduction
The opioid crisis is a pervasive and social problem in the United States. Since 2001
several hundred thousand people have died from the misuse of prescription and illicit opioids.
On average nearly 130 Americans perish every day abusing opioids and millions more struggle
annually with morbidity arising from their opioid use disorders (Hodge, et. al., 2019). This crisis
causes tremendous physical and emotional suffering and death and is likely the most profound
public health crisis our nation has faced. In 2015 alone, 52,000 people died of drug overdoses,
with over 30,000 of those people dying from opioid drugs (Vadivelu, Kai, Kodumudi, Sramcik &
Kaye, 2018). If left unchecked the epidemic will continue to increase, and more of the population
will continue to be affected by the abuse of opioids.
Background
Opioid medications and their derivatives have, for centuries, been viewed as a viable and
legitimate option for the management of pain. However, with approximately 100 million people
suffering from both chronic and acute pain in the United States, opiates will continue to remain a
prominent class of medication in healthcare facilities and homes. Across the United States over
66% of total overdose episodes in 2016 were opioid-related (Stoicea, et. al., 2019). This figure
attests to the severity and wide-spread nature of this issue.
Although providers have complied with the appropriate management of acute and chronic
pain, the short or long-term opioid exposure provides opportunities for long-term opioid misuse
and abuse (Stoicea, et. al., 2019). This then leads to addiction of patients who receive an opioid
prescription. Alarmingly, the overwhelming majority of opioid abusers begin their addiction with
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prescription medications, primarily for chronic pain (Vadivelu, Kai, Kodumudi, Sramcik &
Kaye, 2018).
Defining Concepts and Variables
To minimize any ambiguity, it is important to the process of the Integrative Review (IR)
to appropriately articulate the defining concepts and variables associated with the project. For the
purpose of this project and to understand the intricacy of the problem, there are terms that need
to be defined: opioid addiction, and opioid abuse. West and Brown in their book Theory of
Addiction, defined addiction as a chronic condition in which there is a repeated powerful
motivation to engage in a rewarding behavior, acquired as a result of engaging in that behavior,
that has significant potential for unintended harm. It is not all-or-none, but a matter of degree
(West & Brown, 2013).
The second term is opioid abuse. In general, substance abuse is an initial step toward
addiction and dependence. The World Health Organization (WHO) defines substance abuse as
“the harmful or hazardous use of psychoactive substances, including alcohol and illicit drugs”
(World Health Organization, 2017). Some attributes that characterize substance abuse are failure
to fulfill social or work obligations, continued use of a substance in hazardous situations, legal
problems related to substance abuse, and persistent use despite continued and recurrent problems
(Alzeer, Jones & Bair, 2018).
Rationale for Conducting the Review
Literature related to opioid abuse is vast and expansive. However, the literature seems to
be lacking in the area of screening during the initial assessment to indicate the potential for
abuse. Findings derived from the literature, in context of the clinical question, demonstrates
consistent support in the need for methodologies and interventions to stalemate the opioid abuse
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in society. In addition, data from the articles show the need for elements that prompt intervention
or assist providers in the assessment of patients requiring opioids for management of chronic
pain.
Purpose and/or Review Question
With this in mind, the intent of this project is to determine whether the use of an opioid
screening tool at the initial assessment of patients with chronic non-cancer pain will decrease the
use of opioid use. This not only supports optimal outcomes in the pain management setting of
chronic non-cancer pain (CNCP) patients, but also increases awareness of screening for opioid
abuse among health providers in both acute care and community environments.
Clinical Question
This integrative review will address the following clinical question: In patients with
chronic non cancer pain, does the use of a screening tool at initial assessment compared to those
not screened, influence the reduction of opiate medication use?
Formulate Inclusion and Exclusion Criteria
To further reduce and control data, strict parameters were set via inclusion and exclusion
criteria. These criteria are listed in table 1 and include original studies or systematic reviews in
peer reviewed journals that examined chronic pain. Articles of evidence prior to the year 2016
were excluded to include only more recent studies.
Table 1
Inclusion and Exclusion Criteria:
Inclusion

Exclusion

Articles written in English

Articles written in any language other than
English

OPIOID SCREENING

12

Articles written between 2016-2021

Articles written prior to 2016

Full text article

Unpublished manuscripts, letter to editor, short
article, abstract only, uncompleted clinical trials,
podium speeches

Addressing screening tools for substance abuse

Articles that do not address the intervention of
screening for substance abuse, or screen for other
conditions

Peer reviewed article

Articles that have not gone through peer review
process

Studies with focus of Chronic non-cancer pain

Studies that have a primary focus of acute pain, or
cancer related pain

Conceptual Framework
Integrative reviews require methodological thoroughness supported by framework.
Whittemore and Knafl (2005) note that the integrative review method is the only approach that
allows for the combination of diverse methodologies. It further states, through enhancing its
rigor, this method has the potential to allow for findings from diverse methodologies to be
applied to clinical practice and evidence-based practice initiatives (Whittemore, & Knafl 2005).
The conceptual framework used to guide the project is drawn from Whittemore & Knafl’s (2005)
methodology for critiquing evidence. This was accomplished through synthesis of published
literature that supports the subject matter of interest.
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SECTION TWO: COMPREHENSIVE AND SYSTEMATIC SEARCH
Search Organization and Reporting Strategies
The assistance of a professional librarian was utilized and incorporated in the
development of a search strategy for this integrative review. This allowed for the incorporation
of multiple databases to be utilized along with the prevention of potential bias on the part of the
researcher.
For the purpose of research evidence for the project the use of multiple databases was
employed. The databases utilized include Pub Med, CINAHL Plus with Full Text, Health
Source: Nursing/Academic Edition, Medline, and Nursing & Allied Health Database from the
year 2016-2020. This was completed for referencing studies related to opioids and screening
tools utilized in treatment of chronic pain. The research evidence was drawn from the databases
using key words. The key words utilized were, opioid, abuse, overdose prevention, screening
tools, analgesics, opioid therapeutic use, pain management, chronic pain, and opioid crisis. The
key words were then used in the database search engines in exactly the same order.
Terminology
The databases utilized were a compendium of peer-reviewed scientific works published
by various academic journals. The aforementioned databases were accessed with the rights and
privileges owned by Liberty University. The platforms utilized by these databases were ProQuest
and EBSCO. In addition, the project leader also utilized two software programs that efforted the
categorization and reduction of data. These programs were RefWorks and Covidence. RefWorks
is a citation manager capable of article retention, identification of duplicates and bibliographical
citation. RefWorks was utilized for its ability of data reduction through the incorporation of
Prisma guidelines.
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SECTION THREE: MANAGING THE COLLECTED DATA
Once the articles had been selected from the various databases the selected articles were
then uploaded into RefWorks and then to Covidence where the articles were manually sorted and
duplicates removed along with further data reduction utilizing the Prisma guidelines. The
resulting information can be seen in figure 1. As a result of the large number of articles from the
resulting database search, the project leader made the decision that further databases did not need
to be incorporated into the project.
Figure 1
Prisma 2020 Flow Diagram
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Note: Prisma flow diagram depicting data search and reduction process
Of the 1809 articles screened for the review, 1544 were deemed irrelevant. The resulting
265 articles formed the base and provided the project leader a point at which to begin the
screening process. 215 articles were excluded through inclusion/ exclusion criteria resulting in
50 articles that were then deemed eligible for full text review. 38 of which were excluded for
either wrong setting, patient population, intervention, or study design.
SECTION FOUR: QUALITY APPRAISAL
The process of data analysis is integral to a strong, viable project. Evaluating quality of
primary sources in the integrative review method where diverse primary sources are included
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increases the complexity (Whittemore & Knafl, 2005). The Data analysis stage involves
thematic: coding, categorizing, ordering, and summarizing data found in the articles selected
(Whittemore & Knafl, 2005). In addition, records are kept during the entire data analysis process
to ensure that analytical integrity, as well as process clarity were consistently applied
(Whittemore & Knafl, 2005). Reducing the enormous data to a manageable amount of
information requires various techniques and serves to extract the most important information,
then organize it where the project leader can sort for substance and applicability ensuring that
rigor is maintained (Whittemore & Knafl, 2003).
Sources of Bias
The minimalization of bias is necessary to ensure rigor and applicability to any project.
This project utilized the Prisma guidelines in this regard. The incorporation of these guidelines
helped place specific criteria to minimize the scope of the data. The project leader does
acknowledge that there is the potential of selection bias on the part of the researcher as there is
only one person involved in the procuring of articles. This is inherent to the definition of the
project and all efforts have been made to minimize this bias. As stated previously, this was
mitigated by the utilization of the professional librarian.
Internal Validity
Each article selected for this IR utilized a scientific approach to reach its own individual
conclusion and results. This approach minimized the potential for bias and increased its
individual validity. Thus, due to the use of randomizations, standardized review questions and
cohort studies each was deemed credible and applicable for use.
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Appraisal Tools
Articles in this study were identified, critically appraised, and critiqued for validity
individually and based on Melnyk’s level of evidence and the CASP checklist (Centre for
Evidence-Based Medicine, 2020). A table of evidence is provided in Appendix A. The table
categorically incorporated title, author, study design, method, Melnyk level of evidence, along
with strength and limitation of the study. The CASP checklist was additionally utilized as it is
specifically designed to evaluate qualitative research. It contains 10 questions what were
answered in the affirmative for each article to determine if they presented statistical merit.
Applicability of Results
The literature matrix (Appendix A) served to establish the applicability of each article. As
previously stated, each article was appraised to ensure that each had conclusions and
recommendations that paired with the design, ethical issues, limitations, and discussion of the
study.
Reporting Guidelines
To appropriately recount the structure, bias, and recommendation for this IR, the 2020
PRISMA checklist for systematic reviews was utilized. The identification of this IR was
presented in the title of the manuscript. Structure pertaining to the manuscript are title, abstract,
introduction, methods, results, and discussion. Components incorporated into the body of work
are objectives, synthesis of results, and discussion of bias and recommendations are distinctly
examined within the body of work per PRISMA guidelines.
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SECTION FIVE: DATA ANALYSIS AND SYNTHESIS
Data Analysis Methods: Thematic Analysis
Once the data was appropriately reduced, the next stage was the display and comparison
of common themes within the articles. This process of data visualization and comparison
provides some clarity to the empirical and/or theoretical support emerging from early interpretive
effort and involves an iterative process of examining data displays of primary source data to
identify patterns, themes, or relationships (Whittemore & Knafl, 2005). As previously stated, the
thematic analysis stage involves thematic: coding, categorizing, ordering, and summarizing data
found in the articles selected (Whittemore & Knafl, 2005).
Braun and Clarke (2006) proposed a six step process that enables the identification of
patterns and themes through a collection of literature. The project leader became profoundly
acquainted with each article evaluating each with critical analysis and evaluation. The project
leader then produced initial codes that signified relative information form the data. These codes
were then sorted into potential themes along with creation of a visual representation to better
corelate each. The themes were refined and reviewed with the collection of articles to ensure
they represented that data as a whole. They were then further refined and defined to identify the
overall themes articulated. There were four main themes that emerged throughout the analysis of
the articles.
1. Screening tools are an effective method that offer predictive value with the
provider patient relationship.
2. Screening tools have little effect in managing opioid abuse and are no better than
chance in determining future OUD.
3. Screening tools are not utilized consistently.
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4. There is a lack of consensus as to which screening tool is most effaceable.
Descriptive Results
The articles included in this IR were distributed between qualitative and quantitative
evidence with four articles being ranked level four and the remaining eight being ranked between
level five and six in Melnyk level of evidence. It is notable that there are no articles raking
higher that level four indicating the literature gap and further indication of need of study.
Systematic Review
There were six systematic reviews identified. Lawrence et al., was the first review and
had the purpose to identify validated measurement tools for risk assessment and monitoring of
chronic non-cancer pain patients being considered for, or currently prescribed, analgesic drugs
with abuse potential. The results were that for predicting prescription opioid misuse, the pain
medication questionnaire and the screener and opioid assessment for patients with pain (SOAPP)
had the relevant evidence.
Picco et al., was the second systematic review and had the purpose to confirm the optimal
wording, scoring methods, and cutoff for the OWLS. This review demonstrated that OWLS is a
time-efficient, simple scoring method, allowing for quick and accurate screening for opioid use
disorder to occur.
Greene, et al., was a review that utilized 2014 INSPECT (Indiana's PDMP) data to
identify factors that increase patients' likelihood to engage in opioid-related risk behaviors.
While not a strict screening tool in the same manner as others the project leader felt that this was
still a method of screening that provided strength to the concept. The results concluded that about
one-fourth of all patients consuming opioids engaged in one or more risk behaviors; higher
number of opioid prescriptions and addition of even a small number of benzodiazepine
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prescriptions dramatically increased these odds. PDMPs can be helpful in identifying opioid
users at high-risk for misuse. The strength of this study lies in its size. It consisted of large
sample size, n= 1,538,120 opioid patients.
Nielsen et al., was a review with the intent to develop a short, patient-administered
screening tool that will allow for earlier assessment of prescription opioid dependence (often
referred to as addiction) in primary care settings. This study was able to identify sixty-four
variables associated with criteria for prescription opioid dependence.
Klimas et al., was a systematic review initiated to review the evidence examining factors
associated with opioid addiction and screening tools for identifying adult patients at high vs low
risk of developing symptoms of prescription opioid addiction when initiating prescription
opioids for pain. The results of the study were that while a history of substance use disorder,
certain mental health diagnoses, and concomitant prescription of certain psychiatric medications
appeared useful for identifying patients at higher risk, few quality studies were available and no
symptoms, signs, or screening tools were particularly useful for identifying those at lower risk.
Chaudry et al., was a review with the purpose of to investigate the opioid prescription
patterns of FNPs and their utilization of RMPs in caring for patients with CNMP. The results
derived from the study showed with respect to risk mitigation practices, 50 of the 86 opioidprescribing FNPs reported using treatment contracts with their CNMP patients. Far fewer
(20.9%) used formal screening tools to gauge the risk of opioid abuse and misuse.
Qualitative Study
The IR also identified one qualitative study. Strand et al., is a Qualitative Study of
participating pharmacists who provided screening for 107 patients. The intent of the study is to
design the Opioid Misuse Risk Prevention Toolkit and then evaluate the utility of the toolkit by
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implementing it in community pharmacy practice sites. The project demonstrated the utility and
feasibility of screening for opioid misuse risk at the community pharmacy level.
Cohort Studies
The IR contained five cohort studies included in the IR. Clarke et al, was a study
consisting of 225 consecutive new patients. Its purpose was to analyze the validity of the Opioid
Risk Tool (ORT) in a large diverse population. It should be noted that this was the only study
that did not, in some manner validate the effectiveness of a screening tool for prediction of future
OUD. The results from this study show self-report ORT was not a valid test for the prediction of
future aberrant behaviors in this academic pain management population.
Lee et al., was s study under taken to evaluate Opioid use disorder using the Korean
version of the CAGE-Adapted to Include Drugs, and to investigate clinical predictors that might
be useful to screen for OUD. The results derived from the study were that Opioid questionnaires
did not discriminate OUD effectively on their own. Only when combined with other patient
variables such as sex, comorbid NPD, and CHAI, were the CAGE-AID/Opioid questionnaires
feasible and valid to screen for OUD in clinical practice.
Glanz et al., initiated a study to develop and validate an overdose predictive model which
could be used in primary care settings to assess the need for naloxone. This study consisted of a
cohort of 42,828 patients taking chronic opioid therapy and externally validated the model in
10,708 patients. The results derived from the study were that among patients on chronic opioid
therapy, the predictive model identified 66–82% of all subsequent opioid overdoses.
Black et al., was a cohort study that incorporated 555 patients recruited from pain clinics.
The purpose of the study was to develop a short form of the SOAPP-R by retaining as few items
as possible while maximizing predictive accuracy. The results provide strong preliminary
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support for the SOAPP-8 as a brief screening tool of aberrant opioid-related behavior in chronic
pain patients.
Cheatle et al., was a study with a cohort of 180 patients at the time of initiating opioids
for chronic noncancer pain. The purpose of the study was to examine the risk of developing
aberrant behaviors that might lead to a substance use disorder (addiction) when prescribing
opioids for the relief of chronic noncancer pain in primary care settings. The resulting findings
supported the importance of prescreening patients being considered for opioid therapy and that
prescription of opioids for noncancer pain may carry a lower risk of abuse in selected
populations such as in private, community-based practices.
Synthesis
The consensus of the review is that screening protocols are an effective method and do
offer predictive values in the clinical setting. With this consensus in mind a total of four themes
emerged throughout the course of the review. These can be viewed in a visual representation in
figure 2. The effectiveness and predictive value of screening protocols was noted in 11 of the 12
studies included (Picco, et al., 2020; Greene, et al. 2017; Lawrence, et al., 2017; Lee, et al., 2019;
Nielsen, et al., 202; Chaudhary, et al., 2017; Klimas, et al., 2019; Glanz, et al., 2018; Strand, et
al., 2019; Black, et al., 2018; Cheatle, et al., 2018). The determination that screening protocols
has little effect on opioid use was noted in one article (Clark, et al., 2018). The inconsistent use
of the screening protocol was noted in one article (Chaudhary, et al., 2017). The lack of
consensus as to which screening protocol to use was noted in five articles (Black, et al., 2018,
Nielsen, et al., 2020; Lee, et al, 2019; Lawrence, et al., 2017; Picco, et al., 2020).
Figure 2
Synthesis of Literature
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Ethical Considerations
Ethical considerations are of utmost importance. To comply with ethical standards and to
ensure the protection of human subjects, the DNP project team (student and project Chair)
completed research ethics training to ensure protection of human subjects. The project is
appropriately linked to DNP essentials and submitted for review and approval by the Institutional
Review Board (IRB). In addition, a copy of the student’s Collaborative Institutional Training
Initiative (CITI) Certificate is provided in the appendix A.
TIMELINE
This integrative review was completed from May of 2020 through April of 2021. The
clinical question was formulated and approved by the project chair in June of 2020. Once the
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clinical question was approved the project leader initiated the proposal phase of the project
which was completed March 5, 2021. The project leader initiated a detailed literature review and
analysis which was completed April 2, 2021. The first draft of the manuscript was given to the
project chair April 9, 2021. Revisions to the first draft, submission to a third-part editor and
submission of final draft were completed by beginning of May 2021
SECTION SIX: DISCUSSION
This proposed study contributes to the growing body of syntheses encompassing the
opioid epidemic and its implications. It suggests that the utilization of a screening tool at the
initial assessment translates to decreased use of opioids. Data from the articles show the need for
elements that prompt intervention or assists providers in the assessment of patients requiring
opioids for management of chronic pain. This study makes a new contribution to the existing
literature and highlights the targeted and future methodologies to mitigate opioid abuse in
society.
Implications for Practice/ Future Work
The current body of obtained literature supports raised awareness of the subject matter.
The literature demonstrates that a problem exists related to the high percentage of opioid abuse.
Through synthesis of the acquired articles, the project leader was able to identify factors and
indicators supporting the need for consistent screening assessment of potential abuse in the
administration of opioids. No significant gaps or conflicting evidence was identified in the
review of material. The potential for future work derived from this IR is tremendous. As
previously noted, the fact that no articles ranked higher than level four within the Melnyk level
of evidence is disappointing and demonstrates the continued need for research in this area.
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Dissemination
Dissemination will be accomplished through mediums that include but are not limited to:
peer-reviewed publications, poster presentations, and seminars. The project leader envisions the
presentation could be on a macro and micro level and seeks the information available to a broad
audience of professionals by having the findings published in a recognized medical journal. In
addition, the power point developed for this project will be presented at a local symposium for
internal medicine and primary care providers.
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Literature matrix
In patients with chronic non cancer pain, how does the use of a screening tool at the initial assessment compared to those not screened
influence the reduction of opiate medication use?
Title, Author,
Year

Study
Objective

Validation of
the OWLS, a
Screening
Tool for
Measuring
Prescription
Opioid Use
Disorder in
Primary Care,
Picco, L.,
Middleton,
M., Bruno,
R., Kowalski,
M., &
Nielsen, S.
(2020).
Assessment of
risk behaviors
in patients
with opioid
prescriptions:
A study of
Indiana’s
inspect data,
Greene, M.

To confirm the
optimal
wording,
scoring
methods, and
cutoff for the
OWLS

To utilize 2014
INSPECT
(Indiana's
PDMP) data to
identify factors
that increase
patients'
likelihood to
engage in

Design,
Sampling
Method, &
Subjects
Cross-sectional
analysis of an
online sample
Participants
comprised those
with chronic
noncancer pain
who regularly
used prescription
opioids

Level of
Evidence

Intervention

Results

Strengths and
Limitations of Study

Level 5

Participants selfcompleted an online
version of the
OWLS prescription
opioid use disorder
screening tool and
the Composite
International
Diagnostic Interview
Substance Abuse
module

A time-efficient,
simple scoring
method, allowing for
quick and accurate
screening for opioid
use disorder to occur.

Strengths: validity in a
broader, more generalizable
sample
Limitations: Participants did
not receive detailed
information about the study
until after they had
been screened and identified
as eligible, which may
explain the low conversion
rate/ due to the online selfcomplete
method, meeting eligibility
was determined by selfreport,

Literature review

Level 5

Four risk behaviors
were identified:
Receiving >90
morphine milligram
equivalents (MME),
having >4 opioid
prescribers,
obtaining opioids
from >4 pharmacies,

About one-fourth of all
patients consuming
opioids engaged in one
or more risk behaviors;
higher number of
opioid prescriptions
and addition of even a
small number of
benzodiazepine

Strengths: large sample size
(n ¼ 1,538,120 unique
opioid patients) and
completeness
of the dataset
Limitations: Concurrent use
of opioids and
benzodiazepines was one of
the study’s outcomes.
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S.,
opioid-related
Chambers, R. risk behaviors
A.,
Yiannoutsos,
C. T.,
Wright, E.
R., Steele, G.
K., &
Zollinger, T.
W. (2017).

Re-assessing
the Validity of
the Opioid
Risk Tool in a
Tertiary
Academic
Pain
Management
Center
Population,
Clark, M. R.,
Hurley, R.
W., &
Adams, M. C.
B. (2018).
Systematic
review to
determine

. To analyze
the validity of
the Opioid
Risk
Tool (ORT) in
a large. diverse
population

A cross-sectional
descriptive study.
A total of 225
consecutive new
patients,
aged 18 years or
older

Level 4

To identify
validated
measurement

Systematic
review

Level 5

and concurrent use
of opioids and
benzodiazepines.
Two binary logistic
regression analyses
(engaging in at least
one risk behaviors;
engaging in all four
risk behaviors) and
an ordinal regression
analysis (engaging
in 0-4 risk
behaviors) were
conducted to
identify factors
associated with these
opioid-related risk
behaviors
Data collection
included
demographics,
ORT scores,
aberrant behaviors,
pain intensity scores,
opioid type and
dose, smoking
status, employment,
and marital status

prescriptions
dramatically increased
these odds. PDMPs
can be helpful in
identifying opioid
users at high-risk for
misuse.

PDMPs identify prescribers
by their individual DEA
number. Patients who see
multiple providers at the
same
clinic may be
inappropriately marked as
doctor-shoppers,
because the database is
unable to recognize when
providers
are working together

The self-report ORT
was not a valid test
for the prediction of
future aberrant
behaviors in this
academic pain
management
population

Strengths:
Limitations: likely that
EHR data are not complete
in the domains relevant to
misuse stratification/ the
team member had ample
time to review the EHR and
collect objective data, unlike
a clinician actively seeing
patients
with a limited time window
to review patients’ past
medical history to obtain an
accurate ORT score

Selected databases
were systematically
searched for studies

For predicting
prescription opioid
misuse, the pain

Strengths: the wide range of
databases searched
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which
validated
measurement
tools can be
used to assess
risk of
problematic
analgesic use
in patients
with chronic
pain,
Lawrence,
R., Mogford,
D., Colvin,
L., &
Hardman, J.
G. (2017).
Usefulness of
the Korean
Version of the
CAGEAdapted to
Include Drugs
Combined
With Clinical
Predictors to
Screen for
OpioidRelated
Aberrant
Behavior,
Lee, C.-S.,
Kim, D.,
Park, S.-Y.,
Lee, S. C.,
Kim, Y.-C.,
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tools for risk
assessment and
monitoring of
chronic noncancer pain
patients being
considered for,
or currently
prescribed,
analgesic drugs
with abuse
potential.

To evaluate
Opioid use
disorder using
the Korean
version of the
CAGEAdapted to
Include Drugs,
and to
investigate
clinical
predictors that
might be useful
to screen for
OUD in
conjunction
with the
CAGE-AID/

A single-center,
prospective,
observational
study

Level 4

evaluating tools for
risk of analgesic
misuse, either
before, or during,
analgesic therapy for
chronic
pain, using
predetermined
inclusion/exclusion
criteria. Two
independent
reviewers assessed
abstracts, selected
full texts,
extracted data and
assessed quality.

medication
questionnaire and the
screener and opioid
assessment for patients
with pain (SOAPP)
had the best evidence

Limitations: The lack of
literature regarding
screening tools for nonopioid
medication abuse and our
inability to do a metaanalysis
because of heterogeneity of
studies

Assessed OUD in
patients with chronic
opioid treatment.
Multivariable
logistic models of
the CAGEAID/Opioid
questionnaires
combined with
relevant clinical
predictors were
established. Then,
the receiver
operating
characteristic curve
analysis of the
multivariable
CAGE-AID/Opioid
models was

The multivariable
models of the CAGEAID/Opioid with
sex, comorbid
neuropsychiatric
disorder, and current
heavy drinking are
valid parameters to
screen for OUD, with
the cutoff scores of the
CAGE-AID/Opioid
questionnaires ranging
from 0
to 3 depending on the
presence of the clinical
variables.

Limitations: this is a singlecenter study. Therefore,
there would be biases for
generalizing our results to a
national level
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& Moon, J.
Y. (2019).

Opioid
questionnaires

Development
of a Brief
PatientAdministered
Screening
Tool for
Prescription
Opioid
Dependence
for Primary
Care Settings,
Nielsen, S.,
Picco, L.,
Campbell,

To develop a
short, patientadministered
screening tool
that will allow
for earlier
assessment of
prescription
opioid
dependence
(often referred
to as addiction)
in primary care
settings.
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Cross-sectional
analysis

Level 5

conducted to assess
diagnostic accuracy
to screen for OUD.
Next, we calculated
predicted probability
with >85%
sensitivity and >50%
specificity in each
CAGE-AID and
CAGE-Opioid
model. Using
the optimal value of
the predicted
probability, a cutoff
score of the CAGEAID/Opioid
questionnaires
combined with the
relevant clinical
factors was
suggested to screen
for OUD
Identification of
individual items that
were significantly
associated with
meeting ICD-11
criteria for
prescription opioid
dependence.
Exploratory and
confirmatory factor
analysis were
conducted, and items
were reduced to
identify a small item

Sixty-four variables
associated with criteria
for prescription opioid
dependence were
initially identified.

Limitations: The existing
data set comprised
a sample of CNCP patients
who were prescribed strong
opioids. As such, it is not
clear how findings relate to
those who have been
prescribed weaker opioids,
those
who have been taking
opioids for shorter periods
of time,
or those using opioids for
acute pain
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G., Lintzeris,
N., Larance,
B., Farrell,
M.,
Degenhardt,
L., & Bruno,
R. (2020).
Strategies to
Identify
Patient Risks
of Prescription
Opioid
Addiction
When
Initiating
Opioids for
Pain: A
Systematic
Review,
Klimas, J.,
Gorfinkel, L.,
Fairbairn, N.,
Amato, L.,
Ahamad, K.,
Nolan, S.,
Simel, D. L.,
& Wood, E.
(2019).
Prediction
Model for
Two-Year
Risk of
Opioid
Overdose
Among
Patients
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set that were
discriminative and
shared
a simple underlying
structure

To review the
evidence
examining
factors
associated with
opioid
addiction and
screening tools
for identifying
adult patients
at high vs low
risk of
developing
symptoms of
prescription
opioid
addiction when
initiating
prescription
opioids for
pain
To develop and
validate an
overdose
predictive
model which
could be used
in primary care
settings to

A Systematic
Review

Level 5

Two investigators
independently
assessed quality to
exclude
biased or unreliable
study designs and
extracted data from
higher quality
studies

While a history of
substance use disorder,
certain mental health
diagnoses, and
concomitant
prescription of certain
psychiatric
medications appeared
useful for
identifying patients at
higher risk, few
quality studies were
available and no
symptoms, signs, or
screening tools were
particularly useful for
identifying those at
lower risk.

Limitations: While prior
reviews have attempted to
describe risk factors or
opioid risk
screening tools that can be
used to classify patients into
high- vs low-risk categories,
to our
knowledge, none have
conducted rigorous quality
assessments or used LRs as
a strategy to assess
the diagnostic utility of
screening for risk factors or
screening tools

Retrospective
cohort.
a
cohort of 42,828
patients taking
chronic opioid
therapy

Level 4

Potential predictors
and outcomes
(nonfatal
pharmaceutical and
heroin overdoses)
were
extracted from
electronic health

Among patients on
Limitations: significant case
chronic opioid therapy, mix differences between the
the predictive model
two cohorts
identified 66–82% of
all subsequent opioid
overdoses
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Prescribed
assess the need
Chronic
for naloxone
Opioid
Therapy,
Glanz, J. M.,
Narwaney, K.
J., Mueller,
S. R.,
Gardner, E.
M.,
Calcaterra, S.
L., Xu, S.,
Breslin, K., &
Binswanger,
I. A. (2018).

and externally
validated the
model in 10,708
patients

Use of risk
mitigation
practices by
family nurse
practitioners
prescribing
opioids for
the
management
of chronic
nonmalignant
pain,
Chaudhary,
S., &
Compton, P.
(2017).

Online survey
A national sample
of 856 FNPs

To investigate
the opioid
prescription
patterns of
FNPs and
their utilization
of RMPs in
caring for
patients with
CNMP

Level 5

records. Fatal
overdose
outcomes were
identified from state
vital records. To
match the
approximate shelflife of naloxone, we
used
Cox proportional
hazards regression to
model the 2year risk of
overdose.
Calibration and
discrimination
were assessed
Invited to answer an
online survey about
their utilization of
opioids

With respect to risk
mitigation practices,
50 of the 86 opioidprescribing FNPs
reported using
treatment contracts
with their CNMP
patients. Far fewer
(20.9%) used formal
screening tools
to gauge the risk of
opioid abuse and
misuse

Limitations: difficult to
extrapolate the
survey’s findings to the
general population of FNPs.
Unlike
most practicing FNPs, the
survey respondents were
clinical
preceptors in a graduate
nursing program, thus more
likely to
be familiar with the current
literature and evidencebased
guidelines due to their roles
as teachers
survey

OPIOID SCREENING

35

Moving
opioid misuse
prevention
upstream: A
pilot study of
community
pharmacists
screening for
opioid misuse
risk, Strand,
M. A., Eukel,
H., & Burck,
S. (2019).

To design the
Opioid Misuse
Risk
Prevention
Toolkit and
then evaluate
the utility of
the toolkit by
implementing
it in
community
pharmacy
practice sites

Qualitative Study
participating
pharmacists
provided
screening for 107
patients

Level 6

Development
and Validation
of an EightItem Brief
Form of the
SOAPP-R

To develop a
short form of
the SOAPP-R
by retaining as
few items as
possible while

Cohort Study,
Participants
(N = 555),
recruited from
pain clinics.

Level 4

Pharmacists were
trained in the use of
the toolkit, which
they implemented
within their
community
pharmacy for all
patients receiving
opioid prescriptions.
A triage tool was
used to guide the
process
of screening patients
for opioid use
disorder, red flags,
risk of accidental
overdose, and
misuse of opioids
through the
prescription drug
monitoring program
(PDMP)
completed the 24item SOAPP-R and
participated in a
five-month followup visit to evaluate
aberrant drug-related

This pilot project
demonstrated the
utility and the
feasibility of
screening for opioid
misuse risk at the
community pharmacy
level.

These results provide
strong preliminary
support for the
SOAPP-8 as a brief
screening tool of
aberrant opioid-related

did not collect qualitative
data. The respondents
answered
multiple-choice questions,
with preselected choices,
instead of
open-ended or short-answer
questions.
Limitations: This pilot
project lacks statistical
power, and thus the results
should be viewed from a
qualitative perspective

Limitations: the predictive
accuracy of the SOAPP-8
with other populations, such
as teenagers or cancer
patients, is unknown
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(SOAPP-8),
Black, R. A.,
Mccaffrey, S.
A.,
Villapiano, A.
J., Jamison,
R. N., &
Butler, S. F.
(2018).

maximizing
predictive
accuracy.

Low Risk of
Producing an
Opioid Use
Disorder in
Primary Care
by Prescribing
Opioids to
Prescreened
Patients with
Chronic
Noncancer
Pain, Cheatle,
M. D.,
Gallagher, R.
M., &
O’Brien, C.
P. (2018).

To examine the
risk of
developing
aberrant
behaviors that
might lead to a
substance use
disorder
(addiction)
when
prescribing
opioids for the
relief of
chronic
noncancer pain
in primary care
settings
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Longitudinal,
prospective,
descriptive design
with repeated
measures
a cohort of 180
patients at the
time of initiating
opioids for
chronic
noncancer pain

Level 4

behaviors. Opioid
aberrant-related
behavior was
determined through
self-report,
physician report, and
urine toxicology
screen.
The optimal subset
of SOAPP-R items
to predict aberrant
opioid-related
behavior were
identified
empirically in
conjunction with
content expertise
Standardized
measures of patient
status
and treatments
provided, urine drug
monitoring, and
medical chart audits
were obtained
at the time of
initiating opioids for
chronic noncancer
pain and at three,
six,
and 12 months
thereafter.

behavior in chronic
pain patients.

Supports the
importance of
prescreening patients
being considered for
opioid therapy and that
prescription of opioids
for noncancer pain
may carry a lower risk
of
abuse in selected
populations such as in
private,
community-based
practices

Limitations: potential for
selection bias and the effect
of being monitored both in
the subjects and the
prescribing physicians
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Appendix B

To: Thompson, Ken (Nursing); Wright, Stephen (Nursing)
March 8, 2021
Re: IRB Application - IRB-FY20-21-702 The Effect of a Screening Protocol on Opioid Use: An Integrative Review
Dear Stephen Wright and Kenneth Thompson,
The Liberty University Institutional Review Board (IRB) has reviewed your application in accordance with the Office for Human Research
Protections (OHRP) and Food and Drug Administration (FDA) regulations and finds your study does not classify as human subjects research. This
means you may begin your research with the data safeguarding methods mentioned in your IRB application.
Decision: No Human Subjects Research
Explanation: Your study is not considered human subjects research for the following reason:
“Scholarly and journalistic activities (e.g., oral history, journalism, biography, literary criticism, legal research, and historical scholarship),
including the collection and use of information, that focus directly on the specific individuals about whom the information is collected,” are not
considered research according to 45 CFR 46.102(l)(1).
Please note that this decision only applies to your current research application, and any modifications to your protocol must be reported to the
Liberty University IRB for verification of continued non-human subjects research status. You may report these changes by completing a
modification submission through your Cayuse IRB account.
Also, although you are welcome to use our recruitment and consent templates, you are not required to do so. If you choose to use our
documents, please replace the word research with the word project throughout both documents.
If you have any questions about this determination or need assistance in determining whether possible modifications to your protocol would
change your application's status, please email us at irb@liberty.edu.
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G. Michele Baker, MA, CIP
Administrative Chair of Institutional Research
Research Ethics Office
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